logo

For the Inventor, By the Inventor

Iowa City, IA, United States of America

Douglas R Spitz, Jr

This inventor holds 10 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignees: University of Iowa Research Foundation, Galera Labs, LLC, University of Michigan. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Douglas R Spitz, Jr. Retrieved from https://idiyas.com/inventor/douglas-r-spitz-jr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 60.0

 

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 29(Granted Patents)


Company Filing History:

goldMedal7 out of 925 
 
University of Iowa Research Foundation
 patents
silverMedal3 out of 23 
 
Galera Labs, LLC
 patents
bronzeMedal1 out of 3,536 
 
University of Michigan
 patents
where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 12220420 - Combination therapy for cancer treatment (2025-02-11),
2. 12156863 - Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound (2024-12-03),
3. 11596613 - Compositions and methods for treating cancer (2023-03-07),
4. 11529335 - Compositions and methods for treating cancer (2022-12-20),
5. 11219614 - Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound (2022-01-11),
6. 10052304 - Compositions and methods for cancer therapy (2018-08-21),
7. 9801922 - Compositions and methods of treating cancer (2017-10-31),
8. 9168307 - Mitochondrial-targeted cationic nanoparticles comprising CaMKII inhibitors and uses thereof for treating and preventing diseases and disorders associated with CaMKII activity (2015-10-27),
9. 9090701 - Methods of detecting oxidized calcium/calmodulin dependent protein kinase II (2015-07-28),
10. 8841423 - Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II (2014-09-23),

Title: The Innovative Contributions of Douglas R Spitz, Jr

Introduction

Douglas R Spitz, Jr is a notable inventor based in Iowa City, IA. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 10 patents to his name, Spitz has focused on developing methods that enhance the efficacy of cancer therapies.

Latest Patents

Among his latest patents, Spitz has developed a method for combination therapy for cancer treatment. This method involves administering at least one active agent, which includes a thioredoxin reductase inhibitor and a glutathione depleting agent, alongside a pentaaza macrocyclic ring complex. Another significant patent is for combination cancer therapy that utilizes a pentaaza macrocyclic ring complex and an ascorbate compound. This method includes administering an active agent selected from ascorbic acid, its derivatives, or a pharmaceutically acceptable salt, in conjunction with the pentaaza macrocyclic ring complex.

Career Highlights

Throughout his career, Spitz has worked with reputable organizations such as the University of Iowa Research Foundation and Galera Labs, LLC. His work in these institutions has allowed him to collaborate on groundbreaking research aimed at improving cancer treatment methodologies.

Collaborations

Some of his notable coworkers include Michael K Schultz and Robert A Beardsley. Their collaborative efforts have contributed to the advancement of innovative cancer therapies.

Conclusion

Douglas R Spitz, Jr is a prominent figure in the field of cancer research and treatment innovation. His patents reflect a commitment to improving patient outcomes through advanced therapeutic methods.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…